Everywhere lawmakers go these days, they hear the same complaint: life is getting more expensive. Groceries cost more. Housing costs more. Utilities cost more. And for millions of Americans dealing with chronic health conditions, the cost of staying healthy can feel just as overwhelming.
Among all those concerns, one issue keeps surfacing again and again—insulin.
For families managing diabetes, insulin isn’t a luxury purchase. It isn’t something that can be delayed until next month or skipped when budgets get tight. It’s a necessity. For many Americans, particularly those living with Type 1 diabetes, it is literally the difference between life and death.
That’s what makes the debate over insulin prices so frustrating for many patients and their families. Nearly 8.4 million Americans rely on insulin, yet studies have found that a significant number of users have rationed their medication because they simply couldn’t afford the full cost. Think about that for a moment. In one of the wealthiest nations in the world, people are stretching out doses of life-sustaining medicine because they are worried about paying their bills.
The problem isn’t limited to the uninsured, either.
Even Americans with health insurance increasingly report feeling squeezed by rising premiums, growing deductibles, and mounting out-of-pocket expenses. Having insurance no longer guarantees that critical medications will be affordable.
The good news is that lawmakers don’t have to guess whether insulin price caps can work. There is already a real-world example.
The Inflation Reduction Act capped insulin costs at $35 per month for Medicare beneficiaries. Since that policy took effect, data has shown a substantial reduction in out-of-pocket expenses for seniors. A Johns Hopkins analysis found that the percentage of Medicare patients paying $35 or less for a monthly insulin supply increased dramatically between 2019 and 2023, while average costs fell by more than half.
And the benefits went beyond saving money.
Researchers also found reductions in emergency room visits and hospitalizations among seniors suffering diabetes-related complications. In other words, making insulin more affordable didn’t just help people financially—it helped keep them healthier.
But here’s where the debate gets interesting.
The protections currently stop at Medicare. Millions of Americans with employer-sponsored insurance and many without insurance at all still face much higher insulin costs. A family with a child diagnosed with Type 1 diabetes can still find itself paying hundreds of dollars each month, depending on its insurance plan and coverage.
That reality has prompted a bipartisan group of senators to push for broader reforms.
The proposed INSULIN Act, introduced by Sens. Bill Cassidy, Susan Collins, Raphael Warnock, and John Kennedy, would extend the $35 monthly cap to Americans with employer-sponsored health insurance while also creating pathways for uninsured patients to access more affordable insulin.
What’s notable about the proposal isn’t just the policy itself—it’s the coalition behind it.
In today’s hyper-polarized Washington, finding an issue that attracts strong support from both Republicans and Democrats is increasingly rare. Yet insulin affordability appears to be one of those exceptions. The legislation has drawn support from lawmakers who disagree on almost everything else, reflecting broad public support that crosses ideological lines.
For Cassidy, the issue is also personal. His granddaughter, Elle, was diagnosed with Type 1 diabetes as a child, giving his family firsthand experience with the daily challenges that millions of Americans face. Anyone who has watched a loved one manage diabetes understands the constant monitoring, planning, and vigilance required every single day.
The larger healthcare debate in Washington remains complicated, and solutions rarely come easily. But insulin is one area where policymakers can point to a successful model and measurable results.
The question now is whether Congress is willing to take the next step.
